SPECIAL INVESTIGATION FOR ABRYSVO IN INDIVIDUALS AGED 60 YEARS OR OLDER
← catalyst calendarNCT06546800 · readout in 435 d
Sponsored by Pfizer (industry) · PFE — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
1,100estimated
Sites
1
Country
Japan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-05-27 | actual | When the study began enrolling |
| Primary completion | 2027-10-28 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-10-28 | estimated | The whole study's end, after follow-up |
| First posted | 2024-08-09 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-02-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Respiratory Syncytial Virus Infection
Intervention
- Biological: RSVpreF vaccine — also filed as Abrysvo
Primary outcomes
what the primary-completion date above is the date OFPercentage of individuals aged 60 years or older reporting Adverse Reactions for 28 days after vaccination.
measured From the day of vaccination up to 28 days after vaccination.
Percentage of individuals aged 60 years or older reporting Serious Adverse Reactions from the day of vaccination up to 28 days after vaccination.
measured From the day of vaccination up to 28 days after vaccination.
Permalink · PFE's whole pipeline · Catalyst calendar · Every registered study · What changed